Ichikawa Tatsuki, Miyaaki Hisamitsu, Miuma Satoshi, Motoyoshi Yasuhide, Yamashima Mio, Yamamichi Shinobu, Koike Makiko, Takahashi Youichi, Honda Tetsurou, Yajima Hiroyuki, Uehara Ryouhei, Hino Naoyuki, Hirata Ryousuke, Taura Naota, Nakao Kazuhiko
Department of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Innovation and Translational Research Center, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Biomed Rep. 2020 Mar;12(3):89-98. doi: 10.3892/br.2020.1273. Epub 2020 Jan 24.
Serum creatinine (Cr)-based glomerular filtration rate (CrGFR) is overestimated in liver disease. The present study evaluated whether the difference in CrGFR and cystatin C (CysC) GFR (dGFR) is significant in liver disease. The Cr-to-CysC ratio and sarcopenia index (SI) have been reported to correlate with muscle volume. An estimated total body muscle mass with Cr, CysC and calculated body muscle mass (CBMM) has also been reported to correlate with muscle mass. The applicability of dGFR, SI and CBMM for liver disease were evaluated. A total of 313 patients with liver damage were evaluated for Child-Pugh score, albumin-bilirubin (ALBI) score, model for end-stage liver disease, fibrosis-4, Cr, CysC, Cr-based estimated GFR (CreGFR), CysCGFR and grip strength. Of the 313 patients, 199 were evaluated using cross-sectional computed tomography (CT) of the third lumbar vertebra to determine the skeletal muscle (SM) mass. dGFR, CBMM and SI were compared to liver damage, muscle strength and muscle mass. In the 313 patients, dGFR was correlated with age, ALBI and grip strength; CBMM was correlated with body mass index (BMI) and grip strength; and SI was correlated with BMI and grip strength. In patients evaluated with CT, the correlation coefficients for CBMM and SI with SM were 0.804 and 0.293, respectively. Thus, CBMM and SI were associated with sarcopenia. The relationship between dGFR and ALBI does not differ with different grades of CrGFR-based chronic kidney disease (CKD). dGFR is a marker of liver damage and muscle strength regardless of CKD. CBMM and SI are markers for sarcopenia in liver disease.
基于血清肌酐(Cr)的肾小球滤过率(CrGFR)在肝脏疾病中被高估。本研究评估了在肝脏疾病中CrGFR与胱抑素C(CysC)肾小球滤过率(CysCGFR)的差异(dGFR)是否显著。据报道,Cr与CysC的比值以及肌肉减少症指数(SI)与肌肉体积相关。据报道,通过Cr、CysC估算的全身肌肉总量以及计算得出的身体肌肉量(CBMM)也与肌肉量相关。评估了dGFR、SI和CBMM在肝脏疾病中的适用性。总共对313例肝损伤患者进行了Child-Pugh评分、白蛋白-胆红素(ALBI)评分、终末期肝病模型、纤维化-4、Cr、CysC、基于Cr的估算肾小球滤过率(CreGFR)、CysCGFR和握力评估。在这313例患者中,199例接受了第三腰椎的横断面计算机断层扫描(CT)以确定骨骼肌(SM)量。将dGFR、CBMM和SI与肝损伤、肌肉力量和肌肉量进行比较。在这313例患者中,dGFR与年龄、ALBI和握力相关;CBMM与体重指数(BMI)和握力相关;SI与BMI和握力相关。在接受CT评估的患者中,CBMM和SI与SM的相关系数分别为0.804和0.293。因此,CBMM和SI与肌肉减少症相关。基于CrGFR的不同等级慢性肾脏病(CKD)中,dGFR与ALBI的关系并无差异。无论CKD情况如何,dGFR都是肝损伤和肌肉力量的标志物。CBMM和SI是肝脏疾病中肌肉减少症的标志物。